Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
UCB-0022 by UCB for Parkinson's Disease: Likelihood of Approval
UCB-0022 is under clinical development by UCB and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase II...
UCB-4594 by UCB for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
UCB-4594 is under clinical development by UCB and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to...
UCB-4594 by UCB for Pancreatic Cancer: Likelihood of Approval
UCB-4594 is under clinical development by UCB and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
(Doxecitine + doxribtimine) by UCB for Inherited Mitochondrial Disorders: Likelihood of Approval
(Doxecitine + doxribtimine) is under clinical development by UCB and currently in Phase III for Inherited Mitochondrial Disorders. According to...
Fenfluramine hydrochloride by UCB for Unspecified Genetic Disorders: Likelihood of Approval
Fenfluramine hydrochloride is under clinical development by UCB and currently in Phase III for Unspecified Genetic Disorders. According to GlobalData,...
Dapirolizumab pegol by UCB for Systemic Lupus Erythematosus: Likelihood of Approval
Dapirolizumab pegol is under clinical development by UCB and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...
UCB-7853 by UCB for Parkinson's Disease: Likelihood of Approval
UCB-7853 is under clinical development by UCB and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase I...
Brivaracetam by UCB for Epilepsy: Likelihood of Approval
Brivaracetam is under clinical development by UCB and currently in Phase III for Epilepsy. According to GlobalData, Phase III drugs...
Rotigotine ER by UCB for Frontotemporal Dementia (FTD): Likelihood of Approval
Rotigotine ER is under clinical development by UCB and currently in Phase II for Frontotemporal Dementia (FTD). According to GlobalData,...